E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
aggression and agitation following on from a traumatic brain injury |
|
E.1.1.1 | Medical condition in easily understood language |
aggression and agitation following on from a traumatic brain injury |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Behaviours [F01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Using the Modified Overt Aggression Scale (MOAS) to assess aggression at 12 weeks in order to estimate sample size for future full RCT, and gauge the potential recruitment and drop-out rates. |
|
E.2.2 | Secondary objectives of the trial |
Irritability score on the Irritability Questionnaire (IRQ) and global social function on the Glasgow Outcome Scale-Extended (GOS-E) will be used to establish standard deviations that will inform the power calculation for the full scale RCT.
Data from health-related Quality of life (QoL) measures, EQ-5D-5L and SF-12 will be compared in order to assess their suitability for data collection in this sample. This will allow us to calculate quality adjusted life years (QALYs) in the proposed full scale RCT in future which is necessary to undertake an economic evaluation using the methods preferred by the National Institute of Health and Care Excellence.
To assess the feasibility and suitability of data collection on the adverse events profile using Udvalg for Kliniske Undersøgelser (UKU) scale, and physical health measures.
To assess change in carer wellbeing on the 'Wellbeing' section of the 'Carer Wellbeing and Support Questionnaire (CWS) to establish the sensitivity of the measur |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18 to 65 years. - A confirmed clinical diagnosis of TBI which happened at least six months prior to recruitment. - Referred to the clinician for the management of aggression and for whom the clinician is considering a pharmacological intervention for this problem after investigating and addressing physical, psychological and social triggers. - Is able to give written, informed consent, as judged by a medically qualified doctor. - The patient or their carer is able to understand how to manage prescribed medication, as determined by discussion at the screening assessment.
|
|
E.4 | Principal exclusion criteria |
- Suffering from Post-Traumatic Amnesia (PTA), which constitutes a sub-acute confusional state. - Co-morbid serious mental illness such as schizophrenia and other psychoses, bipolar disorder, major depressive disorder, personality disorder, and dementia. - Already prescribed an antipsychotic drug or any other drug that may interact with risperidone at the time of randomisation. - Any other contraindication for using risperidone including a previous history of severe adverse events. - Has no fixed abode or any other reason for which compliance with trial medication and monitoring could pose a major problem. -Is pregnant or trying to conceive, as determined by self-report. -Lactose intolerance |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The standard deviation of the Modified Overt Aggression Scale (MOAS) score at 12 weeks' follow-up and as changes from baseline will be calculated. These data will inform a sample size calculation for our proposed full scale RCT in future, along with any other relevant published information. The range and mean score change in MOAS from baseline to 12 weeks for those who have scored 'improved' and 'very much improved' according to Clinical Global Impression-Improvement (CGI-I) scale. This information will determine what effect size on MOAS corresponds to a clinically important improvement for an individual patient. This will inform the sample size calculation for the full RCT.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 31 |